<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Targeted cancer therapies &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/targeted-cancer-therapies/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Thu, 15 Jan 2026 21:00:37 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0.2</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Targeted cancer therapies &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Exploring Quinoxalinyl and Quinolinyl Compounds as ALK5 Inhibitors</title>
		<link>https://bioengineer.org/exploring-quinoxalinyl-and-quinolinyl-compounds-as-alk5-inhibitors/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 15 Jan 2026 21:00:34 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[ALK5 inhibitors]]></category>
		<category><![CDATA[Drug synthesis methods]]></category>
		<category><![CDATA[Quinoxalinyl and quinolinyl compounds]]></category>
		<category><![CDATA[Targeted cancer therapies]]></category>
		<category><![CDATA[TGF-β signaling pathway]]></category>
		<guid isPermaLink="false">https://bioengineer.org/exploring-quinoxalinyl-and-quinolinyl-compounds-as-alk5-inhibitors/</guid>

					<description><![CDATA[In a significant advancement in cancer therapeutics, researchers have sharpened their focus on the inhibition of ALK5 (Activin receptor-like kinase 5), an important player in the TGF-β signaling pathway that has been implicated in both oncogenesis and tumor progression. The study led by Liu, C., Li, J., and Lu, YQ. explores the design and synthesis [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">317308</post-id>	</item>
		<item>
		<title>Unraveling WNT Signaling in Cancer: From Molecular Mechanisms to Targeted Therapies</title>
		<link>https://bioengineer.org/unraveling-wnt-signaling-in-cancer-from-molecular-mechanisms-to-targeted-therapies/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 27 Oct 2025 15:48:12 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Molecular oncology]]></category>
		<category><![CDATA[Targeted cancer therapies]]></category>
		<category><![CDATA[tumor microenvironment]]></category>
		<category><![CDATA[Wnt signaling pathway]]></category>
		<category><![CDATA[β-catenin regulation]]></category>
		<guid isPermaLink="false">https://bioengineer.org/unraveling-wnt-signaling-in-cancer-from-molecular-mechanisms-to-targeted-therapies/</guid>

					<description><![CDATA[In the relentless pursuit of innovative cancer therapies, the WNT signaling pathway has emerged as a pivotal molecular axis, commanding intense scientific scrutiny. This ancient and evolutionarily conserved signaling cascade plays a fundamental role in regulating cellular processes such as proliferation, differentiation, and tissue homeostasis. Yet, its dysregulation is a hallmark of oncogenesis, implicated in [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">287191</post-id>	</item>
		<item>
		<title>New Triazole-Oxazole Hybrids Target p53–MDM2 Pathway</title>
		<link>https://bioengineer.org/new-triazole-oxazole-hybrids-target-p53-mdm2-pathway/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 23 Sep 2025 15:31:12 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[fragment-based drug discovery]]></category>
		<category><![CDATA[next-generation cancer treatments]]></category>
		<category><![CDATA[p53-MDM2 pathway]]></category>
		<category><![CDATA[Targeted cancer therapies]]></category>
		<category><![CDATA[triazole-oxazole hybrids]]></category>
		<guid isPermaLink="false">https://bioengineer.org/new-triazole-oxazole-hybrids-target-p53-mdm2-pathway/</guid>

					<description><![CDATA[In the ongoing battle against cancer, researchers have made significant strides in developing targeted therapies that can improve treatment outcomes while minimizing the adverse effects commonly associated with traditional chemotherapy. A groundbreaking study led by A. Prajapati and H. Patel focuses on a pivotal area of cancer biology: the p53-MDM2 pathway. Their innovative research employs [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">271457</post-id>	</item>
		<item>
		<title>HKUMed Reveals Viral Mechanism Driving Nasopharyngeal Cancer Metastasis, Paving Way for Targeted Therapies</title>
		<link>https://bioengineer.org/hkumed-reveals-viral-mechanism-driving-nasopharyngeal-cancer-metastasis-paving-way-for-targeted-therapies/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 04 Sep 2025 20:48:57 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[3D genome architecture]]></category>
		<category><![CDATA[EBV oncogenesis mechanism]]></category>
		<category><![CDATA[Epigenetic cancer research]]></category>
		<category><![CDATA[Epstein-Barr virus mechanism]]></category>
		<category><![CDATA[Nasopharyngeal cancer metastasis]]></category>
		<category><![CDATA[Nasopharyngeal carcinoma metastasis]]></category>
		<category><![CDATA[Targeted cancer therapies]]></category>
		<category><![CDATA[Viral chromatin interaction]]></category>
		<category><![CDATA[Viral genome hijacking]]></category>
		<guid isPermaLink="false">https://bioengineer.org/hkumed-reveals-viral-mechanism-driving-nasopharyngeal-cancer-metastasis-paving-way-for-targeted-therapies/</guid>

					<description><![CDATA[In a groundbreaking study that promises to reshape our understanding of viral oncology, researchers at The University of Hong Kong’s LKS Faculty of Medicine have unveiled a novel mechanism by which the Epstein-Barr virus (EBV) orchestrates the progression and metastasis of nasopharyngeal carcinoma (NPC). This common human virus, long associated with NPC—a cancer predominantly affecting [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">258831</post-id>	</item>
		<item>
		<title>RBM17 Drives Liver Cancer via Lipid, Immunity Changes</title>
		<link>https://bioengineer.org/rbm17-drives-liver-cancer-via-lipid-immunity-changes/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sat, 02 Aug 2025 01:19:38 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Hepatocellular Carcinoma]]></category>
		<category><![CDATA[lipid metabolism reprogramming]]></category>
		<category><![CDATA[RBM17]]></category>
		<category><![CDATA[Targeted cancer therapies]]></category>
		<category><![CDATA[tumor-immune microenvironment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/rbm17-drives-liver-cancer-via-lipid-immunity-changes/</guid>

					<description><![CDATA[In a groundbreaking new study published in Cell Death Discovery, researchers have uncovered critical insights into the molecular mechanisms driving hepatocellular carcinoma (HCC), the most common form of liver cancer globally. The team, led by Wang, Liu, and Lai, has identified the RNA-binding motif protein 17 (RBM17) as a central regulator in the progression of [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">252567</post-id>	</item>
	</channel>
</rss>
